Company Quick10K Filing
Pieris Pharmaceuticals
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 0 $0
10-Q 2019-09-30 Quarter: 2019-09-30
10-Q 2019-06-30 Quarter: 2019-06-30
10-Q 2019-03-31 Quarter: 2019-03-31
10-K 2018-12-31 Annual: 2018-12-31
10-Q 2018-09-30 Quarter: 2018-09-30
10-Q 2018-06-30 Quarter: 2018-06-30
10-Q 2018-03-31 Quarter: 2018-03-31
10-K 2017-12-31 Annual: 2017-12-31
10-Q 2017-09-30 Quarter: 2017-09-30
10-Q 2017-06-30 Quarter: 2017-06-30
10-Q 2017-03-31 Quarter: 2017-03-31
10-K 2016-12-31 Annual: 2016-12-31
10-Q 2016-09-30 Quarter: 2016-09-30
10-Q 2016-06-30 Quarter: 2016-06-30
10-Q 2016-03-31 Quarter: 2016-03-31
10-K 2015-12-31 Annual: 2015-12-31
10-Q 2015-09-30 Quarter: 2015-09-30
10-Q 2015-06-30 Quarter: 2015-06-30
10-Q 2015-03-31 Quarter: 2015-03-31
10-K 2014-12-31 Annual: 2014-12-31
10-Q 2014-09-30 Quarter: 2014-09-30
10-K 2014-06-30 Annual: 2014-06-30
10-Q 2014-03-31 Quarter: 2014-03-31
10-Q 2013-12-31 Quarter: 2013-12-31
8-K 2019-11-09 Earnings, Other Events, Exhibits
8-K 2019-11-05 Regulation FD, Exhibits
8-K 2019-11-04 Enter Agreement, Sale of Shares, Shareholder Rights, Amend Bylaw, Other Events, Exhibits
8-K 2019-10-02 Regulation FD, Exhibits
8-K 2019-10-01 Regulation FD, Exhibits
8-K 2019-09-27 Regulation FD, Exhibits
8-K 2019-09-26 Other Events, Exhibits
8-K 2019-09-20 Regulation FD, Exhibits
8-K 2019-09-03 Officers, Amend Bylaw, Other Events, Exhibits
8-K 2019-08-15 Regulation FD, Exhibits
8-K 2019-08-01 Earnings, Exhibits
8-K 2019-07-31 Officers, Shareholder Vote, Exhibits
8-K 2019-07-31 Officers, Exhibits
8-K 2019-07-26 Regulation FD
8-K 2019-06-16 Regulation FD, Exhibits
8-K 2019-06-06 Regulation FD, Exhibits
8-K 2019-05-22 Regulation FD, Exhibits
8-K 2019-05-16 Regulation FD, Exhibits
8-K 2019-05-14 Regulation FD, Exhibits
8-K 2019-05-10 Earnings, Exhibits
8-K 2019-04-08 Regulation FD, Exhibits
8-K 2019-04-02 Regulation FD, Exhibits
8-K 2019-04-01 Regulation FD, Exhibits
8-K 2019-03-13 Regulation FD, Exhibits
8-K 2019-03-12 Earnings, Exhibits
8-K 2019-01-30 Enter Agreement, Sale of Shares, Shareholder Rights, Amend Bylaw, Exhibits
8-K 2019-01-07 Regulation FD, Exhibits
8-K 2018-11-19 Regulation FD, Exhibits
8-K 2018-11-15 Regulation FD, Exhibits
8-K 2018-11-09 Regulation FD, Exhibits
8-K 2018-11-07 Earnings, Exhibits
8-K 2018-10-25 Officers, Exhibits
8-K 2018-10-24 Enter Agreement, Off-BS Arrangement
8-K 2018-10-02 Regulation FD, Exhibits
8-K 2018-09-19 Regulation FD, Exhibits
8-K 2018-09-16 Regulation FD, Exhibits
8-K 2018-09-07 Officers, Exhibits
8-K 2018-09-05 Regulation FD, Exhibits
8-K 2018-08-09 Earnings, Exhibits
8-K 2018-07-24 Officers, Shareholder Vote, Exhibits
8-K 2018-06-06 Regulation FD, Exhibits
8-K 2018-05-08 Regulation FD, Exhibits
8-K 2018-04-24 Officers, Exhibits
8-K 2018-03-13 Regulation FD, Exhibits
8-K 2018-03-09 Earnings, Exhibits
8-K 2018-02-22 Regulation FD, Exhibits
8-K 2018-02-16 Other Events, Exhibits
8-K 2018-02-14 Enter Agreement, Other Events, Exhibits
8-K 2018-02-13 Other Events, Exhibits
8-K 2018-02-08 Enter Agreement, Exhibits
8-K 2018-01-08 Regulation FD, Exhibits

Pieris Pharmaceuticals Financials

-

PIRS Metrics, Comps, Filings


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Quarter)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Quarter)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Assets Liabilities Revenue Gross Profit Net Income EBITDA EV
IQVIA Holdings (IQV) 31,513,956 23,068,000 16,287,000 10,706,000 0 281,000 1,947,000 42,028,956
Incyte (INCY) 18,623,069 2,947,633 700,442 2,005,874 1,902,719 305,869 372,073 17,205,831
Exact Sciences (EXAS) 14,884,282 1,781,943 1,016,411 623,185 460,190 -220,817 -185,830 14,679,224
Icon (ICLR) 6,885,543 2,354,255 999,974 0 0 0 0 6,489,692
Charles River (CRL) 6,958,639 4,625,484 3,146,641 2,448,962 226,417 220,564 517,541 8,796,441
PRA Health Sciences (PRAH) 6,617,134 3,442,538 2,278,838 2,932,575 0 158,690 356,273 7,591,452
Exelixis (EXEL) 6,657,219 1,643,098 154,466 909,761 827,632 641,536 443,501 6,286,330
Syneos Health (SYNH) 5,202,117 7,396,981 4,573,082 4,546,223 481,502 16,564 470,239 7,829,278
Medpace Holdings (MEDP) 2,312,510 1,016,861 358,806 786,213 0 88,719 146,221 2,292,412
National Research (NRC) 1,399,554 104,275 78,308 0 0 30,382 44,054 1,432,691
Intrexon (XON) 1,235,430 655,188 375,965 134,954 0 -497,264 -451,827 1,322,574
Sorrento Therapeutics (SRNE) 449,036 587,043 532,427 6,929 4,584 -261,935 -221,277 683,809
Eloxx Pharmaceuticals (ELOX) 360,429 79,039 23,815 0 0 -51,554 -51,432 326,058
Luna Innovations (LUNA) 210,317 82,189 17,001 56,872 26,780 11,755 15,601 186,780
Anavex Life Sciences (AVXL) 169,983 21,968 4,337 0 0 -28,209 -28,209 148,733
Bioanalytical Systems (BASI) 20,678 38,644 28,310 37,816 11,279 -1,280 2,026 33,699
Nanoviricides (NNVC) 17,687 13,449 2,848 0 0 -8,424 -7,737 15,131
Cleveland Biolabs (CBLI) 18,190 3,086 943 277 0 -3,042 -3,030 15,590
Tenax Therapeutics (TENX) 3,335 9,664 1,044 0 0 -13,816 -13,811 -5,072
Pieris Pharmaceuticals (PIRS) 116,750 130,840 111,355 27,136 0 -39,941 -39,935 17,050

Balance Sheet ($'000)2013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-30
Cash0011018,47413,16710,02732,25529,34931,18940,37436,55829,35655,24250,32589,92137,878109,52150,57689,48274,867110,80099,700
Accounts Receivable017070583948,4702,53715,5463,3092,5595,3382,7017,1287,174
Inventory
PP&E4,2351,7861,8111,9284,4492,2102,4472,4484,6892,9933,0853,4566,9137,6527,7867,9868,4158,17011,245
Assets0011021,88416,77514,47836,20133,95037,20546,45543,71335,06361,875105,95798,861103,876173,239162,025151,657141,341131,048130,840
Accounts Payable111,2601,5402,0581,1181,0591,7111,6384,5242,3863,3174,6462,6022,4521,9343,1742,6933,3503,7284,031
Long-Term Debt
Liabilities35113,8782,5473,3302,5502,82210,0299,16312,2309,83643,83996,62394,30392,354122,546106,707101,396101,406100,886111,355
Stockholders' Equity18,00614,22711,14733,65131,12827,17637,29231,48225,22718,0369,3344,55811,52250,69355,31850,26139,93530,16219,485
Income Statement ($'000)2013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-30
Revenue00005,3652181604152,1391,2471,0737852,7261,3432,4113,92718,1524,15211,6918,3454,9148,5455,332
Cost of Revenue
Gross Profit
R&D1,5251,7262,0522,9433,6594,5004,6226,9175,3606,1346,2595,2707,9369,15511,40112,99814,29613,373
SG&A
Tax01401630008141461440-1480600
Net Income-2-2-6-14-9,840-3,705-3,530-3,922-2,902-4,161-5,883-6,196-6,559-7,994-10,085-7,0597,490-8,714-203-6,153-11,682-10,348-11,758
Cash Flow ($'000)2013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-30
Cash Operating-1-0-8-14-15,108-10,733
Cash Investing-5,31612,912
Cash Financing201930280